文献速递炎症性肠病

高压氧治疗对因中重度急性发作住院的溃疡性结肠炎患者耐受良好且有效:一项2A期先导性多中心随机双盲假对照试验

Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial.
PubMed 文献 · Am J Gastroenterol · 2018-02-16

这项2A期先导性多中心随机双盲假对照试验因招募不佳提前终止,实际入组18例(计划70例)因中重度急性发作住院的溃疡性结肠炎患者,随机接受激素+每日高压氧(n=10)或激素+每日假高压空气(n=8)。高压氧组第5天和第10天临床缓解率均显著高于假对照组(50% vs 0%,p=0.04),住院期间需升级二线治疗的比例更低(10% vs 63%,p=0.04),无严重不良事件。作者认为需更大样本试验提供确切证据。

要点

  • 高压氧组第5天和第10天临床缓解率均为50%,假对照组为0%(p=0.04)。
  • 高压氧组住院期间升级二线治疗比例10%,假对照组63%(p=0.04)。
  • 因难治性溃疡性结肠炎住院期间需结肠切除比例高压氧组0% vs 假对照组38%(p=0.07)。

核心结论

  • 在这项小型概念验证2A期试验中,高压氧作为激素的辅助治疗用于因中重度急性发作住院的溃疡性结肠炎患者,可提高临床缓解率并降低住院期间升级二线治疗的比例。
  • 作者指出需要更大样本的充分把握度试验来提供确切疗效证据。

研究设计与样本

  • 2A期先导性多中心随机双盲假对照试验,因招募不佳提前终止,实际入组18例(计划70例)。
  • 因中重度急性发作住院的溃疡性结肠炎患者(Mayo评分≥6,内镜亚评分≥2)按区组随机分为激素+每日高压氧组(n=10)或激素+每日假高压空气组(n=8)。
  • 患者对分组设盲,评估由设盲的消化内科医生完成。

主要发现

  • 高压氧组第5天和第10天临床缓解率均为50%,假对照组为0%(p=0.04)。
  • 高压氧组住院期间需升级二线治疗(结肠切除或生物制剂治疗)的比例为10%,假对照组为63%(p=0.04)。
  • 因难治性溃疡性结肠炎住院期间需结肠切除作为二线治疗的比例,高压氧组为0%,假对照组为38%(p=0.07)。
  • 无严重不良事件。

关键数值与推荐

  • 主要结局为研究第5天临床缓解率(部分Mayo评分≤2且无任何亚评分>1)。
  • 关键次要结局包括临床应答(部分Mayo评分降低≥2,直肠出血亚评分0-1)及住院期间升级二线治疗(结肠切除或生物制剂治疗)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因招募不佳提前终止,实际入组18例,计划入组70例。
  • 作者指出需要更大样本的充分把握度试验来提供确切疗效证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperbaric oxygen therapy (HBOT) markedly increases tissue oxygen delivery. Case series suggest it may have a potential therapeutic benefit in ulcerative colitis (UC). We investigated the therapeutic potential of HBOT as an adjunct to steroids for UC flares requiring hospitalization. METHODS: The study was terminated early due to poor recruitment with 18 of the planned 70 patients enrolled. UC patients hospitalized for moderate-severe flares (Mayo score ≥6, endoscopic sub-score ≥2) were block randomized to steroids + daily HBOT (n = 10) or steroids + daily sham hyperbaric air (n = 8). Patients were blinded to study assignment, and assessments were performed by a blinded gastroenterologist. Primary outcome was the clinical remission rate at study day 5 (partial Mayo score ≤2 with no sub-score >1). Key secondary outcomes were: clinical response (reduction in partial Mayo score ≥2, rectal bleeding sub-score of 0-1) and progression to second-line therapy (colectomy or biologic therapy) during the hospitalization. RESULTS: A significantly higher proportion of HBOT-treated patients achieved clinical remission at study day 5 and 10 (50 vs. 0%, p = 0.04). HBOT-treated patients less often required progression to second-line therapy during the hospitalization (10 vs. 63%, p = 0.04). The proportion requiring in-hospital colectomy specifically as second-line therapy for medically refractory UC was lower in the HBOT group compared to sham (0 vs. 38%, p = 0.07). There were no serious adverse events. CONCLUSION: In this small, proof-of-concept, phase 2A trial, the use of HBOT as an adjunctive therapy to steroids for UC patients hospitalized for moderate-severe flares resulted in higher rates of clinical remission, and a reduction in rates of progression to second-line therapy during the hospitalization. Larger well-powered trials are needed, however, to provided definitive evidence of therapeutic benefit.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Buckey JC, Raffals LE, et al. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol. 2018. PMID: 29453383. doi:10.1038/s41395-018-0005-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。